128 related articles for article (PubMed ID: 29089796)
1. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
[TBL] [Abstract][Full Text] [Related]
2. Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.
Srikanthan A; Penner N; Chan KKW; Sabharwal M; Grill A
Curr Oncol; 2018 Aug; 25(4):257-261. PubMed ID: 30111966
[TBL] [Abstract][Full Text] [Related]
3. Provincial elections and timing of cancer drug funding.
Srikanthan A; Gill SS; Chan KK
Curr Oncol; 2016 Jun; 23(3):154-63. PubMed ID: 27330343
[TBL] [Abstract][Full Text] [Related]
4. Determinants of the Cancer Drug Funding Process in Canada.
Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
[TBL] [Abstract][Full Text] [Related]
5. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.
McDonald H; Charles C; Elit L; Gafni A
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586
[TBL] [Abstract][Full Text] [Related]
6. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
Lexchin J
BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
[TBL] [Abstract][Full Text] [Related]
7. Impact of rarity on Canadian oncology health technology assessment and funding.
Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW
Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560
[TBL] [Abstract][Full Text] [Related]
8. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
9. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
Masucci L; Beca J; Sabharwal M; Hoch JS
Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
[TBL] [Abstract][Full Text] [Related]
10. Factors Influencing Delays in Patient Access to New Medicines in Canada: A Retrospective Study of Reimbursement Processes in Public Drug Plans.
Salek S; Lussier Hoskyn S; Johns JR; Allen N; Sehgal C
Front Pharmacol; 2019; 10():196. PubMed ID: 30983993
[TBL] [Abstract][Full Text] [Related]
11. The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison.
Skedgel C
Curr Oncol; 2016 Oct; 23(5):322-328. PubMed ID: 27803596
[TBL] [Abstract][Full Text] [Related]
12. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
Jackson EB; Hotte SJ
Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
[TBL] [Abstract][Full Text] [Related]
13. Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.
Hoch JS; Brown MB; McMahon C; Nanson J; Rozmovits L
Curr Oncol; 2014 Oct; 21(5):263-6. PubMed ID: 25302034
[TBL] [Abstract][Full Text] [Related]
14. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
[TBL] [Abstract][Full Text] [Related]
15. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review.
Rocchi A; Chabot I; Glennie J
Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
Meyers DE; Jenei K; Chisamore TM; Gyawali B
JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
[TBL] [Abstract][Full Text] [Related]
17. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
Niraula S
Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
[TBL] [Abstract][Full Text] [Related]
18. The timing of drug funding announcements relative to elections: a case study involving dementia medications.
Gill SS; Gupta N; Bell CM; Rochon PA; Austin PC; Laupacis A
PLoS One; 2013; 8(2):e56921. PubMed ID: 23460820
[TBL] [Abstract][Full Text] [Related]
19. Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs.
Saluja R; Jiao T; Koshy L; Cheung M; Chan KKW
Curr Oncol; 2021 Jan; 28(1):606-618. PubMed ID: 33498460
[TBL] [Abstract][Full Text] [Related]
20. Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
Lexchin J
BMJ Open; 2017 Oct; 7(10):e018372. PubMed ID: 29061631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
